Bilaal.Raja
Company record

UTMD  UTAH MEDICAL PRODUCTS INC

Trailing twelve months to 2026-06-30, as filed 2026-08-12 and not restated since.
Healthcare

Scale

Market cap
$224m
Revenue TTM
$36m
Net income TTM
$10m
Free cash flow
$11m
Composite score
74.0
Sector rank
#2818

Valuation

P / E
21.4
EV / EBITDA
10.8
EV / sales
3.8
FCF yield
5.11%
Yield vs 10-yr
-0.04pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
29.0%
EBITDA margin
35.1%
ROE
8.6%
ROIC
29.8%
Revenue growth
-7.0%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Analysis of Results of Operations a) Overview Income statement results in second calendar quarter (2Q) and first half (1H) 2026 compared to the same periods of 2025 were as follows: Consolidated total 2Q 2026 revenues were $1,424 (14.3%) lower than in 2Q 2025, with 1H 2026 revenues $2,411 (12.3%) lower than in 1H 2025. The lower sales in comparison with the prior year’s periods were primarily the result of a lack of sales to UTMD’s two previously largest customers, representing a combined $1,065 loss in 2Q 2025 sales, which was 75% of the 2Q decline; and representing a combined $1,923 loss in 1H 2025 sales, which was 80% of the 1H decline. …UTAH MEDICAL PRODUCTS INC, 10-Q, period ended 2026-06-30, filed 2026-08-12

Read the full passage →